10-K · March 23, 2026
Context Therapeutics is a clinical-stage T‑cell engager (TCE) bispecific antibody company advancing three programs (CTIM-76, CT-95, CT-202) toward and into Phase 1. The 10-K emphasizes clinical milestones (IND clearance…
Earnings analysis · 10-Q
CNTX earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Context Therapeutics Inc. reported a net loss of $8.68 million for Q4 2025, which represents a significant increase of 89.6% compared to a net loss of $4.58 million in Q4 2024. The company experienced no revenue during…
Read full summary
Context Therapeutics Inc. reported a net loss of $8.68 million for Q4 2025, which represents a significant increase of 89.6% compared to a net loss of $4.58 million in Q4 2024. The company experienced no revenue during this quarter, continuing a trend of generating no revenue since its inception. Operating expenses surged to $9.34 million, primarily driven by increased research and development activities for its clinical trials.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.14
What stood out
-
No Revenue Recorded
The company reported zero revenue for Q4 2025, maintaining a trend established since inception.
-
Increased Net Loss
Net loss increased by 89.6% to $8.68 million from $4.58 million year-over-year.
-
Surge in Operating Expenses
Overall operating expenses rose sharply to $9.34 million, up from $5.53 million in the prior year, mainly due to R&D expenditure.
-
Cash Reserves Enough Until Mid-2027
As of March 31, 2026, cash and cash equivalents stood at $54.5 million, which the management expects to fund operations into mid-2027.
-
R&D Spending Spike
R&D expenses increased by $3.6 million to $7.02 million compared to $3.46 million in the previous year.
-
Higher Interest Income
Interest income for the quarter was $520,139, down from $958,517, reflecting reduced cash balances.
What to watch
-
Risk of Further Dilution
The company will need to raise additional capital, potentially leading to further dilution for existing shareholders.
-
No Revenue Generation Timeline
The lack of expected revenue generation delays financial stability, with profitability still years away.
-
Dependence on Equity Financing
Future funding requirements may heavily depend on the company’s ability to raise funds through equity offerings, which may not be guaranteed.
Management's outlook
Management stated that they do not expect to generate significant revenue from product sales for several years.
Earlier filings 4
10-Q · August 6, 2025
Context Therapeutics reported no revenue and a wider net loss of $8,827,510 for the three months ended June 30, 2025 (EPS $(0.09)), versus a net loss of $2,254,506 (EPS $(0.04)) in Q2 2024. R&D spending ramped…
10-Q · May 7, 2025
Context Therapeutics reported no revenue for the quarter and a net loss of $4,577,261 (EPS $(0.05)) for the three months ended March 31, 2025. Cash and cash equivalents were $89,352,227 (down $5,077,597 from $94,429,824…
10-K · March 21, 2024
Context Therapeutics is a preclinical biopharma focused on a CLDN6xCD3 bispecific antibody, CTIM-76, with IND-enabling work ongoing and an IND filing expected by the end of March 2024. The company reports strong…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.